利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.024 秒)

    BISPECIFIC ANTIBODY MOLECULES WITH ANTIGEN-TRANSFECTED T-CELLS AND THEIR USE IN MEDICINE
    1.
    发明公开
    BISPECIFIC ANTIBODY MOLECULES WITH ANTIGEN-TRANSFECTED T-CELLS AND THEIR USE IN MEDICINE 审中-公开
    具有抗原转染的T细胞和它们在医学双特异性抗体分子

    公开(公告)号：EP2809682A1

    公开(公告)日：2014-12-10

    申请号：EP13705405.2

    申请日：2013-01-24

    申请人： F.Hoffmann-La Roche AG ,  Ludwig-Maximilians-Universität München

    发明人： BOURQUIN, Carole ,  CASTOLDI, Raffaella ,  ENDRES, Stefan ,  KLEIN, Christian ,  KOBOLD, Sebastian ,  NIEDERFELLNER, Gerhard ,  SUSTMANN, Claudio

    IPC分类号： C07K16/28 ,  C07K16/30

    摘要： The present invention relates to a bispecific (monoclonal) antibody molecule with a first binding domain binding an antigen on CD8+ T-cells that does not naturally occur in and/or on CD8+ T-cells and a second binding domain binding to a tumor specific antigen naturally occurring on the surface of a tumor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor. The invention provides the use of said (bispecific) antibody molecules as a medicament, the (bispecific) antibody molecules for use in a method for the treatment of particular diseases as well as a pharmaceutical composition/medicament comprising said (bispecific) antibody molecules, wherein said (bispecific) antibody molecules are to be administered in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor in a specific treatment regimen. Further aspects of the invention are nucleic acid sequences encoding said bispecific (monoclonal) antibody molecules, vectors. host cells, methods for the production of the (bispecific) antibody molecule as well as a kit comprising the (bispecific) antibody molecule of the invention.

    POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY
    4.
    发明公开
    POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY 审中-公开
    POLYPEPTID-POLYNUKLEOTID-KOMPLEX UND VERWENDUNG BEI DER GEZIELTEN EFFEKTORREST-BEREITSTELLUNG

    公开(公告)号：EP2655413A1

    公开(公告)日：2013-10-30

    申请号：EP11802941.2

    申请日：2011-12-21

    申请人： F.Hoffmann-La Roche AG

    发明人： GERG, Michael ,  HEINDL, Dieter ,  NIEDERFELLNER, Gerhard ,  SCHAEFER, Wolfgang ,  SCHRAEML, Michael ,  TACKE, Michael

    IPC分类号： C07K16/00 ,  C07K16/32 ,  C07K16/18 ,  A61K39/395 ,  A61P35/00

    CPC分类号： C07K16/46 ,  A61K47/6889 ,  C07K16/00 ,  C07K16/18 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/92 ,  G01N33/573 ,  G01N33/6863

    摘要： Herein is reported a polypeptide-polynucleotide-complex as therapeutic agent and its use as tool for the targeted delivery of an effector moiety. The polynucleotide part of the complex is essentially resistant to proteolytic and enzymatic degradation in vivo. Additionally the polypeptide part specifically binds to a compound or structure such as a tissue or organ, a process or a disease. Thus, one aspect as reported herein is a polypeptide-polynucleotide-complex comprising a) a polypeptide specifically binding to a target and conjugated to a first member of a binding pair, b) a polynucleotide linker conjugated at its first terminus to the second member of the binding pair, and c) an effector moiety conjugated to a polynucleotide that is complementary to at least a part of the polynucleotide linker.

    摘要翻译： 本文报道了作为治疗剂的多肽 - 多核苷酸复合物及其作为用于靶向递送效应子部分的工具的用途。 复合物的多核苷酸部分在体内基本上抗蛋白水解和酶降解。 另外，多肽部分特异性结合化合物或结构如组织或器官，过程或疾病。 因此，本文报道的一个方面是多肽 - 多核苷酸复合物，其包含a）特异性结合靶并与结合对的第一个成员缀合的多肽，b）在其第一个末端缀合至第二个 所述结合对，以及c）与多核苷酸缀合的效应部分，所述多核苷酸与所述多核苷酸接头的至少一部分互补。

    METHOD FOR THE SELECTION AND PRODUCTION OF TAILOR-MADE, SELECTIVE AND MULTI-SPECIFIC THERAPEUTIC MOLECULES COMPRISING AT LEAST TWO DIFFERENT TARGETING ENTITIES AND USES THEREOF
    8.
    发明公开
    METHOD FOR THE SELECTION AND PRODUCTION OF TAILOR-MADE, SELECTIVE AND MULTI-SPECIFIC THERAPEUTIC MOLECULES COMPRISING AT LEAST TWO DIFFERENT TARGETING ENTITIES AND USES THEREOF 有权
    选择和制作出定制的，选择性的和多特异性治疗分子有至少两个不同的单位及其方法靶向用途

    公开(公告)号：EP2867255A1

    公开(公告)日：2015-05-06

    申请号：EP13734693.8

    申请日：2013-06-25

    申请人： F.Hoffmann-La Roche AG

    发明人： HEINDL, Dieter ,  HUELSMANN, Peter, Michael ,  KALUZA, Brigitte ,  KOPETZKI, Erhard ,  NIEDERFELLNER, Gerhard ,  TIEFENTHALER, Georg

    IPC分类号： C07K16/00 ,  C07K16/46 ,  A61K39/395

    CPC分类号： C07K16/00 ,  C07K16/32 ,  C07K16/468 ,  C12Q1/26 ,  C12Q1/58 ,  C12Q1/66 ,  G01N33/53 ,  G01N33/563

    摘要： Herein is reported a method for determining a combination of antigen binding sites comprising the steps of (i) determining the binding specificity and/or affinity and/or effector function and/or in vivo half-life of a multitude of bispecific antibodies prepared by combining each member of a first multitude of antibody Fab fragments or scFv antibody fragments with each member of a second multitude of antibody Fab fragments or scFv antibody fragments, and a linker comprising at one of its termini the second member of the first binding pair and at the respective other terminus the second member of the second binding pair, whereby the first multitude specifically binds to a first cell surface molecule and the second multitude specifically binds to a second cell surface molecule, and (ii) choosing the bispecific antibody with suitable binding specificity and/or affinity and/or effector function and/or in vivo half-life and thereby determining a combination of antigen binding sites.

    摘要翻译： 在报告了确定性采矿的方法抗原的组合的结合位点，其包括和/或在通过组合制备双特异性抗体的大量的体内半衰期（I）确定的采矿的结合特异性和/或亲和力和/或效应器功能的步骤 抗体Fab片段或scFv抗体片段与抗体Fab片段或scFv抗体片段的第二多个中的每个构件的第一多个的每个成员，和左在第一结合对的第二构件的末端之一，并在包含 respectivement另一末端的第二结合对，第二构件从而使第一多个特异性结合第一细胞表面分子和所述第二多个特异性地结合到第二细胞表面分子，及（ii）选择具有合适的结合特异性的双特异性抗体和 /或亲和力和/或效应子功能和/或体内半衰期，从而确定性采矿抗原结合位点的组合。